These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 12430941)

  • 1. The therapy of myelofibrosis: targeting pathogenesis.
    Mesa RA
    Int J Hematol; 2002 Aug; 76 Suppl 2():296-304. PubMed ID: 12430941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
    Mesa RA
    Curr Hematol Rep; 2003 May; 2(3):264-70. PubMed ID: 12901349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.
    Mesa RA; Barosi G; Cervantes F; Reilly JT; Tefferi A
    Best Pract Res Clin Haematol; 2006; 19(3):495-517. PubMed ID: 16781486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Mesa RA
    Int J Hematol; 2002 Aug; 76 Suppl 2():193-203. PubMed ID: 12430925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
    Tefferi A
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):18-21. PubMed ID: 12682877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment.
    Dingli D; Mesa RA; Tefferi A
    Intern Med; 2004 Jul; 43(7):540-7. PubMed ID: 15335177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.
    Arora B; Ho CL; Hoyer JD; Mesa RA; Tefferi A
    Haematologica; 2004 Dec; 89(12):1454-8. PubMed ID: 15590395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of myelofibrosis with myeloid metaplasia.
    Tefferi A
    J Clin Oncol; 2005 Nov; 23(33):8520-30. PubMed ID: 16293880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The forgotten myeloproliferative disorder: myeloid metaplasia.
    Tefferi A
    Oncologist; 2003; 8(3):225-31. PubMed ID: 12773744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches in the treatment of myelofibrosis.
    Hennessy BT; Thomas DA; Giles FJ; Kantarjian H; Verstovsek S
    Cancer; 2005 Jan; 103(1):32-43. PubMed ID: 15565565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia.
    Mesa RA; Elliott MA; Tefferi A
    Blood Rev; 2000 Sep; 14(3):121-9. PubMed ID: 10986148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Myelofibrosis: A Moving Target.
    Cerquozzi S; Farhadfar N; Tefferi A
    Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
    Odenike O; Tefferi A
    Semin Oncol; 2005 Aug; 32(4):422-31. PubMed ID: 16202688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.
    Le Bousse-Kerdilès MC; Martyré MC
    Ann Hematol; 1999 Oct; 78(10):437-44. PubMed ID: 10550553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental therapy in myelofibrosis with myeloid metaplasia.
    Verstovsek S; Quintás-Cardama A; Kantarjian H; Tefferi A
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1555-63. PubMed ID: 17107281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.
    Arora B; Mesa R; Tefferi A
    Leuk Lymphoma; 2004 Dec; 45(12):2373-86. PubMed ID: 15621750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide in agnogenic and secondary myelofibrosis.
    Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M
    Br J Haematol; 2001 Nov; 115(2):313-5. PubMed ID: 11703326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelofibrosis with myeloid metaplasia.
    Barosi G
    Hematol Oncol Clin North Am; 2003 Oct; 17(5):1211-26. PubMed ID: 14560783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
    Tefferi A; Barosi G; Mesa RA; Cervantes F; Deeg HJ; Reilly JT; Verstovsek S; Dupriez B; Silver RT; Odenike O; Cortes J; Wadleigh M; Solberg LA; Camoriano JK; Gisslinger H; Noel P; Thiele J; Vardiman JW; Hoffman R; Cross NC; Gilliland DG; Kantarjian H;
    Blood; 2006 Sep; 108(5):1497-503. PubMed ID: 16675707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.